InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,667.14
(
-0.83%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1063
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 192

Monday, 06/11/2018 3:24:37 PM

Monday, June 11, 2018 3:24:37 PM

Post# of 438
ONVO is one of those shit-cap companies that is easy to lose track of due to a perception of futility.

Its treatment for alpha-1-antitrypsin deficiency was granted FDA orphan status. ONVO targets fiscal 2020 for filing an NDA for this treatment

Success with this program would legitimize its focus on the $4B market for therapeutic alternative to organ transplants.

ONVO is seeking a 2nd IND-track program in orphan liver disease.

Cash = $44mn while burning ~$6mn / Q, giving them a runway deep into fiscal 2020
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up